We use some essential cookies to make this website work. These cookies are used to improve your website experience. To find out more about the cookies we use, see our Privacy Policy.
We’d also like to use analytics cookies so we can understand how you use the service and make improvements.
Use these toggles to accept or reject individual cookies. To find out more about the cookies we use, see our Privacy Policy.
To solve cancer, we need to solve data. Despite the abundance of research data, translating this to deliver precision medicine remains challenging.
Over 90% of novel cancer drugs fail early in clinical trials, leading to more and more data being generated, which will yield limited value unless it can be interlinked to generate meaningful biological insights into individualised patient response to therapy.
Concr allows cross-talk between biopharma, diagnostics companies, and healthcare providers by unifying data on a single platform to address meaningful questions in precision oncology.
We adopted established cosmology methods with decades of use to empower iterative learning between disparate sources to integrate limited and sparse data optimally, even with missing data points.
Integrate disparate data and tests from across the pipeline and different indications
Make actionable predictions using 300x less pre-clinical and 7x less clinical data
Assess patient outcome-based added value
Our cloud-based platform effectively integrates diverse data parcels to generate meaningful insights.
Translating advanced modelling and predictions using our unique technology for science and clinical research.
Our partners leverage Concr advanced predictive modelling across every stage of therapeutic development to create shared value for the benefit of cancer patients.
We teamed up with leading astrophysicists to adapt established algorithms for genuine integration of disparate oncology datasets.
We are a diverse group of world leaders and pioneers spanning three generations. We have been curated to answer the hardest questions in precision oncology translation and application.
If you’d like more information or have an enquiry, please contact us.
